002603 以岭药业
交易中 11-06 14:14:39
资讯
新帖
简况
以岭药业(002603.SZ)：中药创新药“小儿连花感冒颗粒”获得药品注册证书
智通财经 · 11-05 15:55
以岭药业(002603.SZ)：中药创新药“小儿连花感冒颗粒”获得药品注册证书
以岭药业三季报：经营现金流改善、新版基药目录落地、循证研究持续推进提供中长期支撑
蓝鲸财经 · 11-02
以岭药业三季报：经营现金流改善、新版基药目录落地、循证研究持续推进提供中长期支撑
以岭药业（002603）10月30日主力资金净买入1324.73万元
证券之星 · 11-02
以岭药业（002603）10月30日主力资金净买入1324.73万元
以岭药业(002603.SZ)发布前三季度业绩，归母净利润10.96亿元，同比增长9.55%
智通财经 · 10-28
以岭药业(002603.SZ)发布前三季度业绩，归母净利润10.96亿元，同比增长9.55%
以岭药业(002603)9月30日股东户数14.05万户，较上期增加0.35%
证券之星 · 10-28
以岭药业(002603)9月30日股东户数14.05万户，较上期增加0.35%
股市必读：以岭药业新发布《关于中药新药健骨关节颗粒药物临床试验申请获得受理的公告》
证券之星 · 10-26
股市必读：以岭药业新发布《关于中药新药健骨关节颗粒药物临床试验申请获得受理的公告》
以岭药业9款通络药物再获“家庭常备药”殊荣
证券之星 · 10-23
以岭药业9款通络药物再获“家庭常备药”殊荣
以岭药业(002603.SZ)子公司健骨关节颗粒药物临床试验申请获受理
智通财经 · 10-22
以岭药业(002603.SZ)子公司健骨关节颗粒药物临床试验申请获受理
股市必读：以岭药业新发布《关于化药创新药LB220-D08缓释片药物临床试验申请获得批准的公告》
证券之星 · 10-22
股市必读：以岭药业新发布《关于化药创新药LB220-D08缓释片药物临床试验申请获得批准的公告》
以岭药业（002603）披露化药创新药LB220-D08缓释片临床试验申请获批，10月20日股价下跌0.13%
证券之星 · 10-20
以岭药业（002603）披露化药创新药LB220-D08缓释片临床试验申请获批，10月20日股价下跌0.13%
以岭药业(002603.SZ)：LB220-D08缓释片药物临床试验申请获得批准
智通财经 · 10-20
以岭药业(002603.SZ)：LB220-D08缓释片药物临床试验申请获得批准
以岭药业：化药创新药LB220-D08缓释片获临床试验批准
格隆汇 · 10-20
以岭药业：化药创新药LB220-D08缓释片获临床试验批准
以岭药业（002603）10月15日主力资金净卖出518.11万元
证券之星 · 10-16
以岭药业（002603）10月15日主力资金净卖出518.11万元
以岭药业荣获阿里健康大药房“2026年度最佳伙伴”
证券之星 · 10-08
以岭药业荣获阿里健康大药房“2026年度最佳伙伴”
源头质控再加码！以岭药业万亩苦杏仁野生基地通过GAP延伸检查
证券之星 · 09-29
源头质控再加码！以岭药业万亩苦杏仁野生基地通过GAP延伸检查
股市必读：以岭药业新发布《关于全资孙公司收到化学原料药欧洲CEP证书的公告》
证券之星 · 09-23
股市必读：以岭药业新发布《关于全资孙公司收到化学原料药欧洲CEP证书的公告》
以岭药业(002603.SZ)孙公司收到阿那曲唑原料药欧洲CEP证书
智通财经 · 09-21
以岭药业(002603.SZ)孙公司收到阿那曲唑原料药欧洲CEP证书
以岭药业（002603）披露实际控制人部分股份质押展期公告，9月14日股价上涨1.25%
证券之星 · 09-14
以岭药业（002603）披露实际控制人部分股份质押展期公告，9月14日股价上涨1.25%
股市必读：以岭药业新发布《关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会的公告》
证券之星 · 09-14
股市必读：以岭药业新发布《关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会的公告》
以岭药业（002603）披露将参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会，9月10日股价下跌1.78%
证券之星 · 09-10
以岭药业（002603）披露将参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会，9月10日股价下跌1.78%
暂无数据
公司概况
公司名称：
石家庄以岭药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-07-28
主营业务：
石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是专利中药产品。公司获得了国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。
发行价格：
34.56
{"stockData":{"symbol":"002603","market":"SZ","secType":"STK","nameCN":"以岭药业","latestPrice":16.1,"timestamp":1793945679000,"preClose":16.11,"halted":0,"volume":11218772,"delay":0,"changeRate":-0.0006,"floatShares":1376000000,"shares":1671000000,"eps":0.8272,"marketStatus":"交易中","change":-0.01,"latestTime":"11-06 14:14:39","open":15.91,"high":16.18,"low":15.87,"amount":180000000,"amplitude":0.0192,"askPrice":16.11,"askSize":498,"bidPrice":16.1,"bidSize":7,"shortable":0,"etf":0,"ttmEps":0.8272,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1793948400000},"marketStatusCode":2,"adr":0,"adjPreClose":16.11,"symbolType":"stock","openAndCloseTimeList":[[1793928600000,1793935800000],[1793941200000,1793948400000]],"highLimit":17.72,"lowLimit":14.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1670705376,"isCdr":false,"pbRate":2.39,"roa":"--","peRate":19.46325,"roe":"9.73%","epsLYR":0.77,"committee":-0.801423,"marketValue":26898000000,"turnoverRate":0.0082,"status":1,"floatMarketCap":22158000000},"requestUrl":"/m/hq/s/002603/tweets","defaultTab":"tweets","newsList":[{"id":"2681046292","title":"以岭药业(002603.SZ)：中药创新药“小儿连花感冒颗粒”获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2681046292","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681046292?lang=zh_cn&edition=full","pubTime":"2026-11-05 15:55","pubTimestamp":1793865334,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的中药创新药“小儿连花感冒颗粒”《药品注册证书》。该药品功能主治为：清热解表，宣肺泄热。用于4～12岁儿童风热感冒，症见鼻塞、流浊涕、咽红肿痛、咳嗽、头痛等，舌红，苔薄黄，脉浮数。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IBBQ","BK0239","159992","BK0097","MEDX","002603","BK0042","BK1574","BK0046","BK0188","06978","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680758647","title":"以岭药业三季报：经营现金流改善、新版基药目录落地、循证研究持续推进提供中长期支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=2680758647","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680758647?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:58","pubTimestamp":1793613530,"startTime":"0","endTime":"0","summary":"现金流改善、基药准入落地，研发投入维持高强度以岭药业2026年三季报显示，公司前三季度营收微增，但利润端表现更好。前三季度经营活动产生的现金流量净额16.09亿元，同比增长25.86%。总体而言，以岭药业2026年三季报呈现的是一条平缓但可验证的线索：经营现金流改善指向营运效率的优化，基药目录落地为精神神经领域品种提供了制度性准入，心血管事件链的循证积累与国际化标准输出延续既有节奏，研发管线按计划推进则为中长期储备后劲。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1793613462082063390","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["SPHQ","BK0097","BK0042","BK4585","002603","BK0239","BK0046","159399","BK0188","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680378699","title":"以岭药业（002603）10月30日主力资金净买入1324.73万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680378699","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680378699?lang=zh_cn&edition=full","pubTime":"2026-11-02 09:08","pubTimestamp":1793581737,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月30日收盘，以岭药业报收于15.48元，上涨1.57%，换手率1.11%，成交量15.29万手，成交额2.36亿元。近5日资金流向一览见下表：以岭药业融资融券信息显示，融资方面，当日融资买入1279.18万元，融资偿还1429.48万元，融资净偿还150.3万元。石家庄以岭药业股份有限公司创建于1992年，是国内领先的中药创新企业，以络病理论为科学基石，自主研发17个专利中药新药，覆盖心脑血管、呼吸、抗衰老、代谢、神经、肿瘤等多个健康领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200003333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0097","BK0239","BK0042","002603","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678495808","title":"以岭药业(002603.SZ)发布前三季度业绩，归母净利润10.96亿元，同比增长9.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678495808","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678495808?lang=zh_cn&edition=full","pubTime":"2026-10-28 21:14","pubTimestamp":1793193281,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布2026年第三季度报告，公司前三季度实现营业收入59.68亿元，同比增长1.72%;归属于上市公司股东的净利润10.96亿元，同比增长9.55%;归属于上市公司股东的扣除非经常性损益的净利润10.6亿元，同比增长9.68%;基本每股收益0.656元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002603"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678465264","title":"以岭药业(002603)9月30日股东户数14.05万户，较上期增加0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678465264","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678465264?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:43","pubTimestamp":1793184186,"startTime":"0","endTime":"0","summary":"证券之星消息，近日以岭药业披露，截至2026年9月30日公司股东户数为14.05万户，较6月30日增加486.0户，增幅为0.35%。在中药行业个股中，以岭药业股东户数高于行业平均水平，截至9月30日，中药行业平均股东户数为5.29万户。从股价来看，2026年6月30日至2026年9月30日，以岭药业区间涨幅为2.33%，在此期间股东户数增加486.0户，增幅为0.35%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800040781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","002603","BK0239","BK0042","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678139014","title":"股市必读：以岭药业新发布《关于中药新药健骨关节颗粒药物临床试验申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678139014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678139014?lang=zh_cn&edition=full","pubTime":"2026-10-26 05:43","pubTimestamp":1792964589,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘，以岭药业报收于15.65元，上涨3.57%，换手率2.04%，成交量28.13万手，成交额4.34亿元。公司公告汇总：以岭药业全资子公司申报的中药新药“健骨关节颗粒”临床试验申请于10月21日获国家药监局受理，拟定功能主治为补肾健骨、活血通络、舒筋止痛，适用于骨关节炎肾虚络瘀证。自受理之日起60日内未收到否定或质疑意见，申请人可按提交方案开展临床试验。公司后续将根据审评进度推进临床研究，并及时披露进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600001440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","002603","BK0188","BK0097","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677614917","title":"以岭药业9款通络药物再获“家庭常备药”殊荣","url":"https://stock-news.laohu8.com/highlight/detail?id=2677614917","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677614917?lang=zh_cn&edition=full","pubTime":"2026-10-23 13:09","pubTimestamp":1792732186,"startTime":"0","endTime":"0","summary":"近日，由家庭医生在线主办的“2025-2026家庭常备药上榜品牌”十周年庆典暨颁奖典礼在北京举行。以岭药业在此次评选中荣获“消费者青睐企业奖”，并在感冒药、心脑血管药领域获评“家庭常备长青上榜企业”。“长青”二字，在家庭常备药榜单的语境中分量不轻。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026102300021096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0042","BK0046","BK0239","BK0188","002603"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677481955","title":"以岭药业(002603.SZ)子公司健骨关节颗粒药物临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2677481955","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677481955?lang=zh_cn&edition=full","pubTime":"2026-10-22 17:38","pubTimestamp":1792661907,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布公告，公司全资子公司北京以岭药业有限公司于2026年10月21日收到国家药品监督管理局核准签发的《受理通知书》，健骨关节颗粒新药临床试验申请获得受理。健骨关节颗粒拟定的功能主治为：补肾健骨，活血通络，舒筋止痛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1510851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","BK0042","002603","BK0046","BK0188","MDTX","IBBJ","PSYK","IBBQ","BK0097","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677601294","title":"股市必读：以岭药业新发布《关于化药创新药LB220-D08缓释片药物临床试验申请获得批准的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677601294","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677601294?lang=zh_cn&edition=full","pubTime":"2026-10-22 03:43","pubTimestamp":1792611790,"startTime":"0","endTime":"0","summary":"截至2026年10月21日收盘，以岭药业报收于15.3元，下跌0.26%，换手率0.64%，成交量8.87万手，成交额1.37亿元。当日关注点交易信息汇总：10月21日主力资金净流入59.24万元，占总成交额0.43%。公司公告汇总：以岭药业自主研发的1类化学新药LB220-D08缓释片获国家药监局批准开展针对非典型溶血性尿毒症综合征的临床试验。公司后续将按要求开展临床研究，相关进展存在不确定性，公司将及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200003382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK1574","002603","BK0239","BK1161","06978","BK0042","159992","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676594694","title":"以岭药业（002603）披露化药创新药LB220-D08缓释片临床试验申请获批，10月20日股价下跌0.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676594694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676594694?lang=zh_cn&edition=full","pubTime":"2026-10-20 22:24","pubTimestamp":1792506259,"startTime":"0","endTime":"0","summary":"截至2026年10月20日收盘，以岭药业报收于15.34元，较前一交易日下跌0.13%，最新总市值为256.29亿元。该股当日开盘15.3元，最高15.47元，最低15.25元，成交额达1.56亿元，换手率为0.74%。近日，石家庄以岭药业股份有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，其自主研发的1类化学新药LB220-D08缓释片获准开展针对非典型溶血性尿毒症综合征的临床试验。公司后续将按要求开展临床研究，相关进展存在不确定性，公司将及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000036886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","002603","BK1574","BK0046","BK0188","159992","BK0097","BK0239","BK1161","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676329663","title":"以岭药业(002603.SZ)：LB220-D08缓释片药物临床试验申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2676329663","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676329663?lang=zh_cn&edition=full","pubTime":"2026-10-20 16:10","pubTimestamp":1792483858,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，LB220-D08缓释片获准开展非典型溶血性尿毒症综合征(aHUS)的临床试验。据悉，LB220-D08为公司自主研发的全新小分子化学药物，是公司具有独立知识产权的1类化学新药。本品为靶向Factor B因子的补体抑制剂。通过靶向抑制B因子，本品可选择性抑制旁路途径，阻止C3转化酶的活化，从而抑制C3a、C5a等毒素的生成以及C5转化酶和膜攻击复合物(MAC，C5b-9)的形成，并保持凝集素和经典途径信号通路的正常功能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","BK0042","BMED","IBBQ","MDTX","BK0097","PSYK","BK0046","002603","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676314663","title":"以岭药业：化药创新药LB220-D08缓释片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2676314663","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676314663?lang=zh_cn&edition=full","pubTime":"2026-10-20 16:03","pubTimestamp":1792483405,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159992","BK0239","BK0097","BK0042","002603","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675512285","title":"以岭药业（002603）10月15日主力资金净卖出518.11万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675512285","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675512285?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:09","pubTimestamp":1792112957,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月15日收盘，以岭药业报收于15.01元，下跌0.4%，换手率0.95%，成交量13.13万手，成交额1.98亿元。近5日资金流向一览见下表：以岭药业融资融券信息显示，融资方面，当日融资买入988.24万元，融资偿还1387.6万元，融资净偿还399.36万元。石家庄以岭药业股份有限公司创建于1992年，是国内领先的中药创新企业，以络病理论为科学基石，自主研发17个专利中药新药，覆盖心脑血管、呼吸、抗衰老、代谢、神经、肿瘤等多个健康领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600008786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0046","BK0042","BK0239","002603","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673731970","title":"以岭药业荣获阿里健康大药房“2026年度最佳伙伴”","url":"https://stock-news.laohu8.com/highlight/detail?id=2673731970","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673731970?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:55","pubTimestamp":1791453308,"startTime":"0","endTime":"0","summary":"2026年9月16日，阿里健康大药房十周年庆典举行，以岭药业获颁“2026年度最佳伙伴”奖。在阿里健康大药房渠道，以岭药业凭借稳定的产品供给和良好的用户口碑，成为平台发展过程中的重要合作伙伴。此次获评“2026年度最佳伙伴”，体现了平台对以岭药业合作价值与双方共建成果的认可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026100800024302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["00241","BK0042","BK1142","BK1501","BK1247","BK1610","HK0000165453.HKD","BK1571","BK1502","002603","BK1189","BK0239","BK1615","BK0046","BK1584","BK1589","BK1591","BK0097","BK1617","BK0188","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671729781","title":"源头质控再加码！以岭药业万亩苦杏仁野生基地通过GAP延伸检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2671729781","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671729781?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:44","pubTimestamp":1790671447,"startTime":"0","endTime":"0","summary":"9月24日，河北省药品监督管理局发布《中药材GAP延伸检查结果公告》，以岭药业苦杏仁野生基地通过河北省药监局组织的GAP延伸检查，综合评定符合要求。截至目前，以岭药业已在全国已在全国20余个省区，创建60余个规模化、标准化中药材种养殖基地。连翘、金银花等八个品种已通过了GAP延伸检查，泽泻、土元等六个品种通过了“三无一全”现场核查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026092900027367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","002603","BK0042","BK0188","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669292121","title":"股市必读：以岭药业新发布《关于全资孙公司收到化学原料药欧洲CEP证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669292121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669292121?lang=zh_cn&edition=full","pubTime":"2026-09-23 02:00","pubTimestamp":1790100050,"startTime":"0","endTime":"0","summary":"公司公告汇总关于全资孙公司收到化学原料药欧洲CEP证书的公告石家庄以岭药业股份有限公司全资孙公司万洋衡水制药有限公司收到欧洲药品质量管理局签发的阿那曲唑原料药欧洲药典适用性证书，证书编号CEP-2026-059-Rev 00。阿那曲唑为非甾体类芳香化酶抑制剂，用于绝经后激素受体阳性乳腺癌患者的治疗。此次获证表明该原料药质量获欧洲规范市场认可，具备进入欧盟及承认CEP证书其他国家市场的资质。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300002431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0042","BK0239","BK0097","BK0046","002603"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669915136","title":"以岭药业(002603.SZ)孙公司收到阿那曲唑原料药欧洲CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2669915136","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669915136?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:00","pubTimestamp":1789981240,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布公告，近日，公司全资孙公司万洋衡水制药有限公司(简称“衡水万洋”)收到欧洲药品质量管理局(EDQM)签发的阿那曲唑原料药的欧洲药典适用性证书(简称“CEP证书”)。据悉，阿那曲唑(Anastrozole)是一种广泛应用于治疗雌激素相关肿瘤的药物。此次衡水万洋获得阿那曲唑CEP证书，表明欧洲规范市场对该原料药质量的认可和肯定，标志着该产品具备以原料药形式进入欧盟及承认CEP证书的其他市场的资质，为公司进一步拓展国际市场带来积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"以岭药业(002603.SZ)孙公司收到阿那曲唑原料药欧洲CEP证书","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002603","BK0046","BK0188","BK0097","BK0042","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667652329","title":"以岭药业（002603）披露实际控制人部分股份质押展期公告，9月14日股价上涨1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667652329","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667652329?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:39","pubTimestamp":1789378776,"startTime":"0","endTime":"0","summary":"公司近日披露《关于实际控制人部分股份质押展期的公告》。公告显示，石家庄以岭药业股份有限公司于2026年9月11日接到实际控制人吴相君通知，其持有的15,000,000股公司股份办理了质押展期，占其所持股份比例4.31%，占公司总股本比例0.90%，质押用途为融资，质权人为中信证券股份有限公司，展期后到期日为2027年9月18日。吴相君资信状况良好，具备资金偿还能力，质押风险可控。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400023598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0042","BK0097","002603","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667680339","title":"股市必读：以岭药业新发布《关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667680339","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667680339?lang=zh_cn&edition=full","pubTime":"2026-09-14 01:23","pubTimestamp":1789320193,"startTime":"0","endTime":"0","summary":"公司公告汇总：以岭药业将于9月16日15:30–17:00参加河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会。关于实际控制人部分股份质押展期的公告石家庄以岭药业股份有限公司于2026年9月11日接到实际控制人吴相君通知，其持有的15,000,000股公司股份办理了质押展期，占其所持股份比例4.31%，占公司总股本比例0.90%，质押用途为融资，质权人为中信证券股份有限公司，展期后到期日为2027年9月18日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400000570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0046","BK0188","BK0239","002603","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666447591","title":"以岭药业（002603）披露将参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会，9月10日股价下跌1.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666447591","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666447591?lang=zh_cn&edition=full","pubTime":"2026-09-10 22:25","pubTimestamp":1789050318,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，以岭药业报收于15.42元，较前一交易日下跌1.78%，最新总市值为257.62亿元。近日，以岭药业披露《关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会的公告》。公告显示，公司将于2026年9月16日15:30-17:00通过网络远程方式参加由河北上市公司协会、河北资本市场之家与深圳市全景网络有限公司联合举办的“2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000042169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0097","BK0239","BK0188","BK0046","BK0042"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793945682443,"stockEarnings":[{"period":"1week","weight":0.0571},{"period":"1month","weight":0.0495},{"period":"3month","weight":-0.0518},{"period":"6month","weight":-0.0403},{"period":"1year","weight":-0.0624},{"period":"ytd","weight":-0.0256}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0396},{"period":"3month","weight":-0.0635},{"period":"6month","weight":-0.1172},{"period":"1year","weight":-0.0704},{"period":"ytd","weight":-0.0703}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石家庄以岭药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"140524人(较上一季度增加0.35%)","perCapita":"9793股","listingDate":"2011-07-28","address":"河北省石家庄市裕华区高新技术产业开发区天山大街238号","registeredCapital":"167070万元","survey":" 石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是专利中药产品。公司获得了国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。","listedPrice":34.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"以岭药业,002603,以岭药业股票,以岭药业股票老虎,以岭药业股票老虎国际,以岭药业行情,以岭药业股票行情,以岭药业股价,以岭药业股市,以岭药业股票价格,以岭药业股票交易,以岭药业股票购买,以岭药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}